[go: up one dir, main page]

PT1965801E - Combina??o de azd2171 e pemetrexed - Google Patents

Combina??o de azd2171 e pemetrexed Download PDF

Info

Publication number
PT1965801E
PT1965801E PT06820574T PT06820574T PT1965801E PT 1965801 E PT1965801 E PT 1965801E PT 06820574 T PT06820574 T PT 06820574T PT 06820574 T PT06820574 T PT 06820574T PT 1965801 E PT1965801 E PT 1965801E
Authority
PT
Portugal
Prior art keywords
azd2171
pemetrexed
human
combination
antiangiogenic
Prior art date
Application number
PT06820574T
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0526132A external-priority patent/GB0526132D0/en
Priority claimed from GB0610708A external-priority patent/GB0610708D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1965801E publication Critical patent/PT1965801E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Ink Jet (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT06820574T 2005-12-22 2006-12-19 Combina??o de azd2171 e pemetrexed PT1965801E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0526132A GB0526132D0 (en) 2005-12-22 2005-12-22 Combination Therapy
GB0610708A GB0610708D0 (en) 2006-05-31 2006-05-31 Combination therapy

Publications (1)

Publication Number Publication Date
PT1965801E true PT1965801E (pt) 2011-05-25

Family

ID=37964934

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06820574T PT1965801E (pt) 2005-12-22 2006-12-19 Combina??o de azd2171 e pemetrexed

Country Status (19)

Country Link
US (1) US20080306094A1 (pt)
EP (1) EP1965801B1 (pt)
JP (1) JP2009520787A (pt)
KR (1) KR20080077678A (pt)
AT (1) ATE502641T1 (pt)
AU (1) AU2006328201B2 (pt)
BR (1) BRPI0620118A2 (pt)
CA (1) CA2631676A1 (pt)
CY (1) CY1111482T1 (pt)
DE (1) DE602006020919D1 (pt)
DK (1) DK1965801T3 (pt)
HR (1) HRP20110365T1 (pt)
IL (1) IL191797A0 (pt)
NO (1) NO20082566L (pt)
NZ (1) NZ568812A (pt)
PL (1) PL1965801T3 (pt)
PT (1) PT1965801E (pt)
SI (1) SI1965801T1 (pt)
WO (1) WO2007071970A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
CA2558346A1 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
AU2006264620B2 (en) * 2005-07-06 2009-10-22 Astrazeneca Ab Combination therapy of cancer with AZD2171 and gemcitabine
DK1971338T3 (da) * 2005-12-22 2011-05-23 Astrazeneca Ab Kombination af ZD6474 og pemetrexed
US20090221615A1 (en) * 2008-02-29 2009-09-03 Guru Reddy Combination anti-cancer agents
JP6182313B2 (ja) 2010-03-08 2017-08-16 スペクトラム ファーマシューティカルズ インコーポレイテッド 癌治療のためのチオキサントンをベースとしたオートファジー阻害剤療法
AU2016298439B2 (en) * 2015-07-30 2018-11-08 Expression Pathology, Inc. Quantifying FR-alpha and GART proteins for optimal cancer therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420335B1 (en) * 1998-06-15 2002-07-16 Dana Farber Cancer Institute, Inc. Combination of radiotherapy and anti-angiogenic factors
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
CA2558346A1 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
EP1761281A1 (en) * 2004-06-04 2007-03-14 Pfizer Products Incorporated Method for treating abnormal cell growth
EP1796672A1 (en) * 2004-09-27 2007-06-20 AstraZeneca AB Cancer combination therapy comprising azd2171 and imatinib
AU2006264620B2 (en) * 2005-07-06 2009-10-22 Astrazeneca Ab Combination therapy of cancer with AZD2171 and gemcitabine
EP3168234A1 (en) * 2005-12-15 2017-05-17 Medimmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
DK1971338T3 (da) * 2005-12-22 2011-05-23 Astrazeneca Ab Kombination af ZD6474 og pemetrexed

Also Published As

Publication number Publication date
HK1123976A1 (en) 2009-07-03
AU2006328201B2 (en) 2010-08-19
NZ568812A (en) 2011-09-30
BRPI0620118A2 (pt) 2011-11-01
NO20082566L (no) 2008-07-31
US20080306094A1 (en) 2008-12-11
SI1965801T1 (sl) 2011-06-30
CY1111482T1 (el) 2015-08-05
WO2007071970A3 (en) 2007-08-09
CA2631676A1 (en) 2007-06-28
EP1965801A2 (en) 2008-09-10
WO2007071970A2 (en) 2007-06-28
DE602006020919D1 (de) 2011-05-05
DK1965801T3 (da) 2011-06-14
PL1965801T3 (pl) 2011-07-29
KR20080077678A (ko) 2008-08-25
HRP20110365T1 (hr) 2011-06-30
JP2009520787A (ja) 2009-05-28
AU2006328201A1 (en) 2007-06-28
EP1965801B1 (en) 2011-03-23
ATE502641T1 (de) 2011-04-15
IL191797A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
IL191796A0 (en) Combination of zd6474 and pemetrexed
SI1551409T1 (sl) Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
MX2007005356A (es) Terapia de combinacion que comprende zd6474 y un antiadrogenico.
GB0316127D0 (en) Combination therapy
GB0406446D0 (en) Combination therapy
GB0406445D0 (en) Combination therapy
ZA200600188B (en) Combination therapy
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine